Gianfrancesco Gallino

Gianfrancesco Gallino

Auto-generated profile, based on publicly available information

Gianfrancesco Gallino

National Cancer Institute

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2002 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FBFiliberto Belli
Filiberto Belli
alessandro testorialessandro testori
alessandro testori
LRLicia Rivoltini
Licia Rivoltini
MMMichele Maio
Michele Maio
GAGiovanna Andreola
Giovanna Andreola
GPGiorgio Parmiani
Giorgio Parmiani
PURPOSE: To determine the immunogenicity and antitumor activity of a vaccine consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients.PATIENTS AND METHODS: Sixty-four patients had surgical resection of metastatic tissue required for vaccine production, 42 patients were able to receive the vaccine, and 39 were assessable after one cycle of vaccination (four weekly injections). In 21 patients, a second cycle (four biweekly injections) was given because no progression occurred. Antigen-specific antimelanoma T-cell response was assessed by enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMCs) obtained before and after vaccination. Immunohistochemical analyses of tumor tissues were also performed.RESULTS: No treatment-related toxicity was observed. Of 28 patients with measurable disease, two had a complete response (CR) and three had stable disease (SD) at the end of follow-up. Duration of CR was 559+ and 703+ days, whereas SD lasted for 153, 191, and 272 days, respectively. ELISPOT assay with PBMCs of 23 subjects showed a significantly increased number of postvaccination melanoma-specific T-cell spots in 11 patients, with clinical responders displaying a high frequency of increased T-cell activity. Immunohistochemical staining of melanoma tissues from which vaccine was produced revealed high expression of both HLA class I and melanoma antigens in seven of eight clinical responders (two with CR, three with SD, and the three with long-term disease-free survival) and in four of 12 nonresponders.CONCLUSION: Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity. This vaccine induced clinical and tumor-specific T-cell responses in a significant minority of patients.

14 May 2015 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
RDRiccardo Danielli
Riccardo Danielli
RPRoberto Patuzzo
Roberto Patuzzo
AGAnna Maria Di Giacomo
Anna Maria Di Giacomo
GGGianfranco Gallino
Gianfranco Gallino
AMAndrea Maurichi
Andrea Maurichi
MSMario Santinami
Mario Santinami

2 December 2009 in Cancer
Verified
Journal Article
Open access
PDF file
ISIyad Sultan
Iyad Sultan
CRCarlos Rodriguez‐Galindo
Carlos Rodriguez‐Galindo
HEHani El‐Taani
Hani El‐Taani
GPGuido Pastore
Guido Pastore
MCMichela Casanova
Michela Casanova
AFAndrea Ferrari
Andrea Ferrari
BACKGROUND: Colorectal cancer is exceedingly rare in children and adolescents. Reports from small series indicate that poor prognostic factors are more common in children than in adults, resulting in worse outcome for the pediatric population.METHODS: The Surveillance, Epidemiology, and End Results database was searched for records of children/adolescents with colorectal cancer, and the features and outcomes were compared with those of adults.RESULTS: From January 1973 through December 2005, only 159 children/adolescents (ages 4‐20 years) were reported with a diagnosis of colorectal cancer. The most common sites of involvement were the rectum (27%) and the transverse colon (26%). Adenocarcinoma was the most common histiotype in both adults and pediatric patients; however, children/adolescents had more unfavorable histiotypes (ie, mucinous adenocarcinoma [22%] and signet ring cell carcinoma [18%]) when compared with adults (10% and 1%, respectively; P < .001). Poorly differentiated and undifferentiated tumors (grades III and IV, respectively) and distant stage were more common in children/adolescents (P < .001). The 5‐year relative survival estimates in children/adolescents and adults were 40% ± 4.2% and 60% ± 0.10%, respectively, confirming a worse outcome in the pediatric age group (P < .001).CONCLUSIONS: Children/adolescents represent a minority of patients with colorectal cancer and have high‐risk features and worse outcome than adults. The small number of patients in this age group was an impediment to the development of meaningful clinical trials. Thus, the principles of management for adult colorectal cancer should be used in the treatment of children and adolescents. Cancer 2010. © 2009 American Cancer Society.

1 May 2008 in Cancer Letters
Verified
Journal Article
Closed access
MFM. Frattini
M. Frattini
GGG. Gallino
G. Gallino
SSStefano Signoroni
Stefano Signoroni
DBD. Balestra
D. Balestra
LLLara Lusa
Lara Lusa
MPM.A. Pierotti
M.A. Pierotti

1 April 2012 in Molecular Cancer Research
Verified
Journal Article
Closed access
JRJames F. Reid
James F. Reid
VSViktorija Sokolova
Viktorija Sokolova
EZEugenio Zoni
Eugenio Zoni
ALAndrea Lampis
Andrea Lampis
SPSara Pizzamiglio
Sara Pizzamiglio
MPMarco A. Pierotti
Marco A. Pierotti
Altered expression of miRNAs is associated with development and progression of various human cancers by regulating the translation of oncogenes and tumor suppressor genes. In colorectal cancer, these regulators complement the Vogelstein multistep model of pathogenesis and have the potential of becoming a novel class of tumor biomarkers and therapeutic targets. Using quantitative real-time PCR, we measured the expression of 621 mature miRNAs in 40 colorectal cancers and their paired normal tissues and identified 23 significantly deregulated miRNAs. We subsequently evaluated their association with clinical characteristics of the samples and presence of alterations in the molecular markers of colorectal cancer progression. Expression levels of miR-31 were correlated with CA19-9 and miR-18a, miR-21, and miR-31 were associated with mutations in APC gene. To investigate the downstream regulation of the differentially expressed miRNAs identified, we integrated putative mRNA target predictions with the results of a meta-analysis of seven public gene expression datasets of normal and tumor samples of colorectal cancer patients. Many of the colorectal cancer deregulated miRNAs computationally mapped to targets involved in pathways related to progression. Here one promising candidate pair (miR-1 and MET) was studied and functionally validated. We show that miR-1 can have a tumor suppressor function in colorectal cancer by directly downregulating MET oncogene both at RNA and protein level and that reexpression of miR-1 leads to MET-driven reduction of cell proliferation and motility, identifying the miR-1 downmodulation as one of the events that could enhance colorectal cancer progression. Mol Cancer Res; 10(4); 504–15. ©2012 AACR.

10 August 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAndrea Maurichi
Andrea Maurichi
RMRosalba Miceli
Rosalba Miceli
TCTiziana Camerini
Tiziana Camerini
LMLuigi Mariani
Luigi Mariani
RPRoberto Patuzzo
Roberto Patuzzo
MSMario Santinami
Mario Santinami
Purpose: Cutaneous melanoma incidence is increasing. Most new cases are thin (≤ 1 mm) with favorable prognoses, but survival is nonetheless variable. Our aim was to investigate new prognostic factors and construct a nomogram for predicting survival in individual patients. Patients and Methods: Data from 2,243 patients with thin melanoma were retrieved from prospectively maintained databases at six centers. Kaplan-Meier survival and crude cumulative incidences of recurrence were estimated, and competing risks were taken into account. Multivariable Cox regression was used to investigate survival predictors. Results: Median follow-up was 124 months (interquartile range, 106 to 157 months); 12-year overall survival was 85.3% (95% CI, 83.4% to 87.2%). Median times to local, regional, and distant recurrence were 79, 78, and 107 months, respectively. Relapse was significantly related to age, Breslow thickness, mitotic rate (MR), ulceration, lymphovascular invasion (LVI), and regression; incidence was lower and subgroup differences were less marked for distant metastasis than for regional relapse. The worst prognosis categories were age older than 60 years, Breslow thickness more than 0.75 mm, MR ≥ 1, presence of ulceration, presence of LVI, and regression ≥ 50%. Breslow thickness more than 0.75 mm, MR ≥ 1, presence of ulceration, and LVI (all P = .001) were significantly associated with sentinel node positivity. Age, MR, ulceration, LVI, regression, and sentinel node status were independent predictors of survival and were used to construct a nomogram to predict 12-year overall survival. The nomogram was well calibrated and had good discriminative ability (adjusted Harrell C statistic, 0.88). Conclusion: Our findings suggest including LVI and regression as new prognostic factors in the melanoma staging system. The nomogram appears useful for risk stratification in clinical management and for recruiting patients to clinical trials.